ArticlePloS one2024
Evaluation of the performance of a qPCR-based assay for HIV-1 viral load determination.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAccording to the YY/T 1182-2010 standard of the People's Republic of China on nucleic acid amplification test reagents (kits) for medical industry, the accuracy, precision, linear range, and analytic sensitivity of HIV-1 standardized quality control products should be assessed. The Geneway HIV-1 Nucleic Acid Detection Kit from China has been successfully registered with the National Medical Products Administration. Here, we aimed to assess for the first time its detection performance.
methodsThe accuracy, precision, analytic sensitivity, and linearity of the Geneway HIV-1 nucleic acid quantification test kit were analyzed using a series of diluted standard control samples of HIV-1 negative plasma. Clinical plasma samples were collected from 163 HIV-infected patients and 38 HIV-negative patients. The detection performance of the Geneway assay was compared with that of the US FDA-approved COBAS AmpliPrep/COBAS® Taqman® HIV-1 test (Roche), version 2.0, for viral load (VL) monitoring.
resultsThe absolute deviation of the assay between the logarithm of the measured concentration and the logarithm of the expected concentration did not exceed ±0.5 logarithmic units. All coefficients of variation (CV%) for the assays were within 5%, indicating good precision in the detection. The linearity of quantitation was excellent (r = 0.999). Overall agreement was observed in 198 of the 201 specimens (98.51%), with a kappa value of 0.953. Bland-Altman analysis revealed an average difference of 0.030 between the two assays, with 95.95% (142/148) of the differences falling within the 95% confidence limits of agreement (-0.50, 0.56). Linear regression results demonstrated a strong linear correlation between the two assays, with a high Pearson correlation coefficient (r = 0.980) and coefficient of determination (R2 = 0.960, p < 0.001).
conclusionsThe Geneway HIV-1 VL assay demonstrated excellent accuracy, precision, analytic sensitivity, and linearity. Compared to the Roche assay, the Geneway assay showed good performance for HIV-1 VL detection, supporting its use in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.